Robert Half Up 22% Against a Falling Market: What the Q3 Filing Shows

Seoul — The S&P 500 fell 0.52%, the Nasdaq Composite 0.21% and the Russell 2000 (the U.S. small-cap index) 0.29% on Oct. 23, yet Robert Half Inc. (RHI) rose 21.7%. It filed an earnings report the day before, so its reason is the clearest. Genmab A/S (GMAB) rose on a reported Phase 3 result, but what its same-day SEC filing contains could not be confirmed. Netskope, Inc. (NTSK) rose with cybersecurity peers and filed nothing.

Basis: closing prices for the U.S. trading day of Oct. 23, 2026. Sources are SEC EDGAR filings and news headlines.

At a glance

Robert Half Inc. (RHI): Q3 results beat expectations, 32% in two days

Robert Half Inc. (RHI) closed at $45.87, up 21.74%, after its third-quarter results. It had also risen 8.78% the day before, so the gain is 32.4% over two days and 37.7% over five. It hit a 52-week high of $46.73 intraday (Investing.com). About $316.2 million changed hands, roughly 6.7% of its $4.7 billion market value in one day.

According to an 8-K (a current report to the SEC) filed for Oct. 22, the company issued a press release on third-quarter earnings. The items are 2.02 (results of operations) and 9.01 (exhibits), and the press release is attached as Exhibit 99.1. The 8-K is "furnished" and the filing body contains no revenue or profit figures, so the claim that results beat expectations rests on press coverage, not the filing. Yahoo Finance's headline asks why the stock jumped more than 20%, Simply Wall Street cites "an earnings beat and stronger Q4 outlook," and TIKR says the Talent Solutions segment grew "for the first time" since 2022. Quiver Quantitative reads it as a hiring recovery.

Whether this holds is unclear. The move is large for a single earnings report, and a 12-month price target of $37.89 shown on TradingView sits below the close, though it appears to predate the rise. Two things to check: whether Exhibit 99.1 gives a numerical Q4 outlook, and whether dollar volume holds the next session.

Genmab A/S (GMAB): reported Phase 3 result lifts it 9.5%, but the filing's contents are unconfirmed

Genmab A/S (GMAB) rose 9.48% to $43.79 on reports of a positive Phase 3 result for an ovarian cancer therapy. About $564.7 million traded, against a market value of about $26.9 billion. The stock had already gained 18.4% over five days.

GuruFocus reported positive Phase 3 RAINFOL-02 results, and Investing.com's headline says the stock surged 9% on positive Phase 3 ovarian cancer results. A 6-K, the report non-U.S. companies file with the SEC, was posted the same day, but its items and text could not be confirmed, so it is unclear whether it contains the trial result. The headlines give no trial figures such as the primary endpoint. Media-quoted gains of 7.86% and 9% differ from the close, which can reflect when they were calculated.

A trial result is the kind of news that can be verified by numbers and documents, but with only headlines available it is classified here as an expectation. Check whether the 6-K body contains the result, and whether specific figures are released.

Netskope, Inc. (NTSK): no stated reason, rose with cybersecurity peers

Netskope, Inc. (NTSK) rose 9.37% to $24.28. The company filed nothing with the SEC in the past seven days, so there is no reason from the company itself.

TipRanks' headline says cybersecurity stocks climbed, with Cloudflare (NET) and Netskope up 7%. That points to a sector move rather than company news. The 7% in the headline versus the 9.37% close can reflect timing. The stock also rose 10.04% on Oct. 21, and is up 11.3% over two days and 27.8% over five. About $208.8 million traded, against a market value of about $9.9 billion.

A rise that rides a sector can fade when the sector cools. Check whether the cybersecurity rally continues the next session, and whether the company discloses a catalyst of its own in an 8-K.

What happened to the stocks we covered earlier

Only two of the eight, Braze and Lionsgate, rose afterward. The three filing-backed names split: Braze edged up, while Strive and Disc Medicine fell about 5% to 6%. A filing did not keep a price from giving back its gain.